Claims for Patent: 7,723,361

Summary for Patent: 7,723,361

Title:	Methods for inhibiting undesired angiogenesis in patients having tumors with thalidomide
Abstract:	The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis and to treat disease states resulting from angiogenesis. Importantly, these compounds can be administered orally.
Inventor(s):	D'Amato; Robert (Lancaster, PA)
Assignee:	Celgene Corporation (Summit, NJ)
Application Number:	11/096,155
Patent Claims:	1. A method for inhibiting undesired angiogenesis in a human having a blood born tumor comprising orally administering to said human a capsule comprising an angiogenesis-inhibiting amount of thalidomide and administering an amount of a compound that is an epoxide hydrolase inhibitor. 2. The method of claim 1 wherein the thalidomide is administered in an amount between approximately 0.1 and approximately 300 mg/kg/day. 3. The method of claim 2 wherein the thalidomide is administered in an amount between approximately 0.5 and 50 mg/kg/day. 4. The method of claim 3 wherein the thalidomide is administered in an amount between approximately 1 and approximately 10 mg/kg/day. 5. The method of claim 1 wherein the blood born tumor is leukemia. 6. The method of claim 1, wherein the epoxide hydrolase inhibitor is administered to said human together with thalidomide. 7. The method of claim 1, wherein the thalidomide and the epoxide hydrolase inhibitor are administered to said human sequentially.